| Human clinical trials, |
| Study participants n > 100 |
| Measurement of the participant's DPD‐phenotype in plasma (uracil and/or dihydrouracil) Treatment with systemic treatment with 5‐FU, Capecitabine or Tegafur (teysuno), |
| Data regarding adverse events after treatment, |
| Cancer treatment |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.